decisionhealth Newsletters, Part B News - 2001 Issue 9 (September)
Bill would cut reimbursement for chemotherapy, other drugs
Subscribe or sign in to view the full article.
Article Overview
This article covers proposed federal changes to Medicare reimbursement for certain physician-administered drugs and the policy debate behind them. It explains why lawmakers, oversight agencies, and specialty groups are discussing payment reform, practice expense concerns, and the broader effects on oncology and other provider settings. The piece is relevant to coders, billing staff, and compliance professionals who follow Medicare Part B drug payment policy and related legislative activity.
Why This Topic Matters
Medicare drug-payment methodology affects how office-administered therapies are reimbursed, how practices cover overhead, and how compliance teams interpret payment policy changes. The article also highlights oversight findings that may influence future legislative and administrative updates.
What You Will Learn
- The policy background behind Medicare reimbursement for physician-administered drugs
- Why oversight agencies and lawmakers have raised concerns about drug pricing and payment levels
- How specialty practices such as oncology and ESRD clinics are affected by proposed changes
- What kinds of reimbursement reform options were being discussed
- How end-of-life chemotherapy utilization entered the policy debate
Who Should Read This
- Medical coders
- Billing specialists
- Revenue cycle staff
- Compliance professionals
- Oncology practice administrators
- Medicare policy analysts
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com